

* * * COMMUNICATION RESULT REPORT (DEC. 17.2001 12:33AM) * * *

TTI NNNA

FILE MODE	OPTION	ADDRESS (GROUP)	RESULT	PAGE
809	MEMORY TX	17037465220	OK	P. 4/4

REASON FOR ERROR

E-1) HANG UP OR LINE FAIL
E-3) NO ANSWERE-2) BUSY
E-4) NO FACSIMILE CONNECTION

Telefax



No. of pages incl. this:

Telefax no.: 703 - 746 - 5220

To: Please Deliver to E. (L. Hobbs)

CC:

From: Elias Lambiris

Message:

!Telefax



novozymes

No. of pages incl. this:

Telefax no.: 703 - 746-5220

To: Please Deliver to E. (L. Hobbs)

CC:

From: Elias Lambiris

Message:

Confidential information may be contained in this fax and is intended only for the use of the addressee. If you are not the addressee, please do not copy or deliver this to anyone else. If you receive this telefax by mistake, please telephone the sender. Thank you.

**Novozymes
North America, Inc.
Patents**

405 Lexington Av.,
Suite 6400
New York
NY 10174

Telephone:
(212)-867-0123
Telefax:
(212)-867-0298

Web:
www.novazymes.com

Attorney Docket No.: 3469.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al. Confirmation No: 5039

Serial No.: 09/189,028 Group Art Unit: 1652

Filed: November 10, 1998 Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

AMENDMENT UNDER 37 C.F.R. 1.312Commissioner for Patents
Washington, DC 20231

Sir:

Please amend the above-identified application as follows:

IN THE ABSTRACT OF THE DISCLOSURE:

Please add the attached abstract of the disclosure as page 61 of the specification.

REMARKS


The Notice of Allowance indicated that claims 50-70 are allowed. These claims were added by Amendment mailed December 7, 1999. However, the Amendment omitted claim 59. Therefore, the allowed claims should be claims 50-58 and 60-70. Applicants request that the claims be renumbered to be continuous.

An abstract of the disclosure has been added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: December 17, 2001



Elias J. Lambris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123